Home Medical Devices Global Artificial Pancreas System Market Size, Trends, Top Share, Report to 2032

Artificial Pancreas System Market

Artificial Pancreas System Market Size, Share & Trends Analysis Report By Type (Threshold Suspended Device System, Control to Range (CTR) System, Control to Target (CTT) System), By End User (Hospitals, Ambulatory Surgical Centers (ASCs), Clinics, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRMD56347DR
Study Period 2020-2032 CAGR 8.8%
Historical Period 2020-2022 Forecast Period 2024-2032
Base Year 2023 Base Year Market Size USD 373.65 million
Forecast Year 2032 Forecast Year Market Size USD 757.50 million
Largest Market North America Fastest Growing Market Asia Pacific
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The global artificial pancreas system market size was valued at USD 373.65 million in 2023. It is estimated to reach USD 757.50 million by 2032, growing at a CAGR of 8.8% during the forecast period (2024–2032).

An artificial pancreas system is an advanced medical technology designed to automatically regulate blood glucose for people with diabetes, mainly Type 1 diabetes. An artificial pancreas system brings together continuous glucose monitoring technology with an insulin-delivery device such as an insulin pump—controlled by advanced algorithms, re-creating the glucose-regulatory function of a healthy pancreas.

The global Artificial Pancreas Systems (APS) market is expected to grow from an upsurge in the prevalence of diabetes, technological advancements, and growing awareness about the management of diabetes. The integration of advanced technologies such as continuous glucose monitoring and insulin pumps, which offer better glucose control for patients has significantly improved the functionality of artificial pancreas systems. Additionally, there is growing adoption of digital health solutions together with artificial intelligence driven algorithms in artificial pancreas systems, facilitating more precise and personalized management of diabetes. 

Market Dynamics

Global Artificial Pancreas System Market Drivers

Increasing Prevalence of Diabetes 

Among the artificial pancreas systems, the global market is largely driven by the increase in the incidence rate of diabetes, particularly Type 1 diabetes. According to the International Diabetes Federation, millions of people are diagnosed with diabetes every year, posing an increasing demand for effective and automated solutions for managing diabetes. The more the number of diabetes patients, the higher the demand for advanced technologies such as artificial pancreas systems, which help maintain optimum blood glucose levels with as little manual intervention as possible. As the awareness and diagnosis rates rise, the market for artificial pancreas systems is only going to grow.

Growing Awareness and Adoption of Digital Health Solutions 

Digital health and telemedicine solutions are increasingly gaining awareness, being another significant driver for the artificial pancreas systems market. As more patients and their healthcare providers recognize the benefits of integrating digital technologies into diabetes management, the adoption of artificial pancreas systems is rising. These systems are equipped with remote monitoring capabilities, data analytics, and integration with mobile health applications, all enabling better patient engagement and more personalized care. The convenience and improved outcomes provided by digital health solutions have rendered artificial pancreas systems one of the attractive options for both patients and healthcare providers.

Global Artificial Pancreas System Market Restraint

Complexity and User Training Requirements

There is a general hindrance in the adoption of artificial pancreas systems since they are complex systems that require some form of user training. The patients need to understand and be able to handle complex technology, which can be intimidating for older adults and those not accustomed to technology. The initial setup, calibration, and continuing management require a significant amount of technical capability and regular interaction. Some case studies show that the complexity of artificial pancreas systems leads to wrong use or misuse by the users, who find it hard to trust the system; thus, good control of diabetes is not achieved.

Global Artificial Pancreas System Market Opportunities

Technological Innovations and Integration

The continued development in technology offers substantial opportunities for the artificial pancreas systems market. Continuous improvements, in the form of newer sensors for continuous glucose monitoring, smarter ways of insulin delivery, and the incorporation of artificial intelligence and machine learning algorithms, could greatly add to performance and user experience within artificial pancreas systems. For example, predictive analytics through AI would provide a more accurate and proactive adjustment to insulin delivery, which in turn would improve glucose control and lower the risks of complications. This also opens the way for the further development of more advanced, robust, and user-friendly solutions with the growth in the market.

Strategic Collaborations and Partnerships

Strategic collaborations and partnerships among the manufacturers can accelerate the development and adoption of artificial pancreas systems. Partnerships among medical device manufacturers, technology firms, research institutions, and healthcare providers can foster innovation and fast-track the commercialization of new products. For instance, a partnership with major tech giants like Google or Apple could put artificial pancreas systems into common consumer health platforms and, by that, improve accessibility and user engagement. Such partnerships will also help break down regulatory and market entry barriers that can foster a quicker pace of market expansion.

Regional Analysis

Based on region, the global artificial pancreas system market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

North America Dominates the Global Market

North America is the most significant global artificial pancreas system market shareholder and is expected to expand substantially during the forecast period. North America has a high population, and diabetes prevalence, especially Type 1 diabetes. The Centers for Disease Control and Prevention indicate that in the United States, over 34 million people have diabetes, with around 1.6 million having Type 1 diabetes. This serious health burden in the country results in a high market need for advanced solutions for diabetes management, an artificial pancreas system being one of them. The region also house many companies for medical devices and is a center for research institutions which contribute to an environment fit for further innovation and technological advancement in artificial pancreas systems.

The United States artificial pancreas system market is leading in terms of market share. A strong presence of leading medical device manufacturers and research institutions in the United States is further fostering innovation in the country and propelling the growth of advanced diabetes management technologies. For example, the FDA approved the MiniMed 670G system by Medtronic as the first commercially available hybrid closed-loop insulin delivery system. The approval of this product has led to further product advancements and an increase in the adoption of the artificial pancreas system. Secondly, the conducive reimbursement policies and insurance coverage for devices and diabetes-related services in the United States further incentivize patient adoption of the artificial pancreas system, thereby increasing the market.

The Canadian artificial pancreas system market is poised to grow significant prevalence of diabetes, with approximately 11 million people living with diabetes or prediabetes, according to Diabetes Canada. Moreover, Canada has a vigorous tradition of research in medicine and innovation; several research institutions and healthcare centers in the country are actively engaging in diabetes research and clinical trials. For instance, the University of Alberta in Canada conducted groundbreaking research on the first successful clinical trial of an artificial pancreas system using the Diabeloop DBLG1 system. This research further contributes to the advancement of the artificial pancreas system field and encourages its market growth by validating the effectiveness of these technologies.

These factors are estimated to drive the North American artificial pancreas system market growth.

Asia-Pacific region is a pivotal market for the artificial pancreas system industry, significant number of individuals with diabetes. According to the International Diabetes Federation, the Asia-Pacific region harbors around 60% of the world's diabetic population. The prevalence of diabetes is soaring in countries such as China, India, and Japan, where lifestyle alterations, urbanization, and an aging population are contributing to this fast-increasing burden of the disease. Therefore, a significant market demand for advanced diabetes management solutions like the artificial pancreas systems exists to address the diverse needs of patients in the region.

China's artificial pancreas system market has a major role in shaping the dynamics of the In China, apart from high diabetes prevalence, the country's rapid process of urbanization and aging population become the most important driving force for the artificial pancreas system market. Urbanization is associated with changes in the mode of life, among which are activities such as sedentary behaviour and unhealthy dietary habits, which may increase the risk of diabetes. Besides high diabetes prevalence, the rapidly aging population in China adds to the diabetes burden since older adults are susceptible to diabetes-related complications.

Indian artificial pancreas systems and digital health ecosystem is rapidly evolving, with the widespread adoption of smartphones and internet connectivity.  This digital transformation provides an opportunity for the adoption of telehealth solutions and remote monitoring platforms, in turn incorporating artificial pancreas systems for the management of diabetes. Moreover, India's government initiatives, such as the NPCDCS (National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke), focus on promoting preventive healthcare and improving access to diabetes care services.

Thus, the factors above are estimated to boost the Asia-Pacific artificial pancreas system market growth.

Report Scope

Report Metric Details
Segmentations
By Type
  1. Threshold Suspended Device System
  2. Control to Range (CTR) System
  3. Control to Target (CTT) System
By End User
  1. Hospitals
  2. Ambulatory Surgical Centers (ASCs)
  3. Clinics
  4. Others
Company Profiles Medtronic Plc Bigfoot Biomedical Johnson & Johnson Services Inc. Tandem Diabetes Care, Inc., Pancreum, Inc. TypeZero Technologies, LLC Beta Bionics
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Singapore Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The global artificial pancreas system market is segmented by type, pressure, vehicle type, engine type, and sales channel.

Based on type, the global artificial pancreas system market is divided into threshold suspended device system, control to range (CTR) system and control to target (CTT) system. 

The threshold suspended device system segment dominates the global market for artificial pancreas systems, as it plays an essential role in preventing hypoglycemia—the most critical concern of people with diabetes. These systems automatically suspend the flow of insulin when glucose levels reach or drop below a predefined threshold, thereby minimizing the risk of extreme low-blood-sugar levels. For example, MiniMed 530G with SmartGuard technology, manufactured by Medtronic, has significantly been in use due to its effectiveness in reducing the frequency of hypoglycemia occurrences. This, when coupled with its relative ease of use and proven safety, has ensured a speedy increase in patient and clinician acceptance and will continue to propel its growth in the market.

Based on end users, the global artificial pancreas system market is hospitals, ambulatory surgical centers (ASCs), clinics and others. 

The hospitals are estimated to own the market, due to their role as primary centers for advanced diabetes management and treatment. The necessary infrastructure and expertise available at hospitals ensures the handling of complex cases, provision of comprehensive patient education, and device calibration and monitoring. Further they often lead clinical trials and pilot programs, thus strongly propagating adoption and trust in artificial pancreas systems technology within the healthcare community, in the process consolidating the market power of hospitals.

Market Size By Type

Market Size By Type
  • Threshold Suspended Device System
  • Control to Range (CTR) System
  • Control to Target (CTT) System
  • Recent Developments

    • In April 2023, the FDA authorized the MiniMed 780G artificial pancreas device from Medtronic for use in people seven years of age and older. With its meal detecting technology, the system offers real-time and automatic corrections of blood sugar levels at 5-minute intervals, including correction doses. This approval greatly increased the company's revenue and expanded its product portfolio.
    • In January 2020, the FDA authorized the UVA-Developed Artificial Pancreas system, popularly referred to as Control-IQ. It effectively tracks and controls the blood glucose levels of individuals with type 1 diabetes.

    Analyst’s Perspective

    As per our research analysts, the global artificial pancreas systems market is poised for robust growth driven by technological advancements, increasing prevalence of diabetes, and rising awareness about advanced diabetes management solutions. Innovations in continuous glucose monitoring (CGM) and insulin delivery technologies, coupled with the integration of artificial intelligence (AI) for predictive analytics, are significantly elevating the efficacy and user-friendliness of artificial pancreas systems. Further, enormous investment in research and development by leading medical device companies, favourable regulatory environments, and increasing acceptance among healthcare providers and patients are expected to further accelerate the market uptake. With these systems showing their potential in improving patient outcomes and the quality of life, the market for artificial pancreas systems is poised for strong expansion in the years ahead.

    Key Players

    Artificial Pancreas System Market Share of Key Players

    Artificial Pancreas System Market Share of Key Players
    Medtronic Plc Bigfoot Biomedical Johnson & Johnson Services Inc. Tandem Diabetes Care, Inc., Pancreum, Inc. TypeZero Technologies, LLC Beta Bionics Others

    Frequently Asked Questions (FAQs)

    How big is the artificial oancreas system market?
    The global artificial pancreas system market size was valued at USD 373.65 million in 2023. It is estimated to reach USD 757.50 million by 2032, growing at a CAGR of 8.8% during the forecast period (2024–2032).
    Increasing prevalence of diabetes, growing awareness and adoption of digital health solutions are some key drivers supporting the growth of the artificial oancreas system market.
    North America region has the highest growth rate in the artificial oancreas system market.
    The key players in the global artificial oancreas system market include Medtronic Plc, Bigfoot Biomedical, Johnson & Johnson Services Inc., Tandem Diabetes Care, Inc.,, Pancreum, Inc., TypeZero Technologies, LLC, Beta Bionics.
    Threshold suspended device system segment is the leading segment for the market during forecast period.


    We are featured on :